603456 九洲药业
已收盘 06-18 15:00:00
资讯
新帖
简况
每周股票复盘：九洲药业（603456）子公司获两款药品注册证书
证券之星 · 02:30
每周股票复盘：九洲药业（603456）子公司获两款药品注册证书
股市必读：九洲药业（603456）6月17日董秘有最新回复
证券之星 · 06-18 01:32
股市必读：九洲药业（603456）6月17日董秘有最新回复
九洲药业(603456.SH)子公司获得药品注册证书
智通财经 · 06-16
九洲药业(603456.SH)子公司获得药品注册证书
九洲药业：公司投资者热线电话为0576-88706789
证券之星 · 06-12
九洲药业：公司投资者热线电话为0576-88706789
九洲药业：诺欣妥相关业务是重要组成部分
证券之星 · 06-08
九洲药业：诺欣妥相关业务是重要组成部分
九洲药业：公司积极推出2026年股份回购计划
证券之星 · 06-02
九洲药业：公司积极推出2026年股份回购计划
九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务
证券之星 · 06-02
九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务
九洲药业(603456.SH)：克立硼罗获批上市
智通财经 · 06-02
九洲药业(603456.SH)：克立硼罗获批上市
每周股票复盘：九洲药业（603456）拟回购2-4亿元股份
证券之星 · 05-31
每周股票复盘：九洲药业（603456）拟回购2-4亿元股份
九洲药业（603456）披露拟回购股份公告，5月27日股价下跌0.86%
证券之星 · 05-27
九洲药业（603456）披露拟回购股份公告，5月27日股价下跌0.86%
九洲药业(603456.SH)拟2亿元至4亿元回购公司股份
智通财经 · 05-25
九洲药业(603456.SH)拟2亿元至4亿元回购公司股份
每周股票复盘：九洲药业（603456）拟注销773.6万股回购股份
证券之星 · 05-24
每周股票复盘：九洲药业（603456）拟注销773.6万股回购股份
股市必读：九洲药业（603456）今年截至5月15日累计跌幅已超25%
证券之星 · 05-18
股市必读：九洲药业（603456）今年截至5月15日累计跌幅已超25%
5月14日九洲药业创60日新低，富国双债增强债券A基金重仓该股
证券之星 · 05-14
5月14日九洲药业创60日新低，富国双债增强债券A基金重仓该股
每周股票复盘：九洲药业（603456）拟每10股派1元并注销773.6万股
证券之星 · 05-10
每周股票复盘：九洲药业（603456）拟每10股派1元并注销773.6万股
长城国瑞证券：给予九洲药业增持评级
证券之星 · 05-08
长城国瑞证券：给予九洲药业增持评级
九洲药业（603456）披露2025年年度股东会会议资料，5月6日股价下跌1.38%
证券之星 · 05-06
九洲药业（603456）披露2025年年度股东会会议资料，5月6日股价下跌1.38%
4月27日九洲药业跌5.84%，富国双债增强债券A基金重仓该股
证券之星 · 04-27
4月27日九洲药业跌5.84%，富国双债增强债券A基金重仓该股
异动快报：九洲药业（603456）4月24日10点45分触及跌停板
证券之星 · 04-24
异动快报：九洲药业（603456）4月24日10点45分触及跌停板
九洲药业(603456.SH)发布一季度业绩，归母净利润1.72亿元，同比下降31.22%
智通财经 · 04-23
九洲药业(603456.SH)发布一季度业绩，归母净利润1.72亿元，同比下降31.22%
加载更多
公司概况
公司名称：
浙江九洲药业股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-10
主营业务：
浙江九洲药业股份有限公司的主营业务是提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是合同定制类、抗感染类、中枢神经类药物、非甾体类药物、降血糖类药、贸易类及其他。公司荣获2025中国医药CDMO企业20强、国家知识产权示范企业、2024年度中国医药工业主营业务收入前100位企业、2025年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉，同时公司已入选富时罗素社会责任指数系列。
发行价格：
15.43
{"stockData":{"symbol":"603456","market":"SH","secType":"STK","nameCN":"九洲药业","latestPrice":13.12,"timestamp":1781766000000,"preClose":12.97,"halted":0,"volume":16170101,"delay":0,"changeRate":0.0116,"floatShares":889000000,"shares":889000000,"eps":0.733,"marketStatus":"已收盘","change":0.15,"latestTime":"06-18 15:00:00","open":12.94,"high":13.24,"low":12.84,"amount":212000000,"amplitude":0.0308,"askPrice":13.12,"askSize":237,"bidPrice":13.11,"bidSize":134,"shortable":0,"etf":0,"ttmEps":0.733,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":12.97,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":14.27,"lowLimit":11.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":889446028,"isCdr":false,"pbRate":1.31,"roa":"--","peRate":17.899045,"roe":"1.95%","epsLYR":0.82,"committee":0.204565,"marketValue":11670000000,"turnoverRate":0.0182,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","floatMarketCap":11670000000},"requestUrl":"/m/hq/s/603456","defaultTab":"news","newsList":[{"id":"2644063760","title":"每周股票复盘：九洲药业（603456）子公司获两款药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063760","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063760?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:30","pubTimestamp":1781893834,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，九洲药业报收于13.12元，较上周的12.78元上涨2.66%。本周，九洲药业6月18日盘中最高价报13.24元。本周关注点公司公告汇总：子公司获富马酸伏诺拉生片和西格列汀二甲双胍缓释片药品注册证书公司公告汇总浙江九洲药业股份有限公司子公司九洲生物医药（台州）有限公司、浙江九洲生物医药有限公司近日收到国家药品监督管理局核准签发的富马酸伏诺拉生片、西格列汀二甲双胍缓释片《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644172381","title":"股市必读：九洲药业（603456）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644172381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644172381?lang=zh_cn&edition=full","pubTime":"2026-06-18 01:32","pubTimestamp":1781717532,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，九洲药业报收于12.97元，上涨2.85%，换手率2.11%，成交量18.74万手，成交额2.42亿元。富马酸伏诺拉生片用于反流性食管炎及幽门螺杆菌根除，注册分类为化学药品4类，上市许可持有人为九洲生物医药（台州）有限公司。西格列汀二甲双胍缓释片适用于成人2型糖尿病患者，注册分类为化学药品3类，上市许可持有人为浙江九洲生物医药有限公司，生产单位为广州玻思韬控释药业有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643734765","title":"九洲药业(603456.SH)子公司获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643734765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643734765?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:42","pubTimestamp":1781595772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司子公司九洲生物医药(台州)有限公司、浙江九洲生物医药有限公司收到国家药品监督管理局核准签发的富马酸伏诺拉生片、西格列汀二甲双胍缓释片的《药品注册证书》。富马酸伏诺拉生片适用于反流性食管炎，与适当的抗生素联用以根除幽门螺杆菌。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642265517","title":"九洲药业：公司投资者热线电话为0576-88706789","url":"https://stock-news.laohu8.com/highlight/detail?id=2642265517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642265517?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:27","pubTimestamp":1781252868,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问可否告知董秘办电话多少，谢谢！九洲药业回复：您好，感谢您对公司的关注与支持，公司投资者热线电话为：0576-88706789。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641104082","title":"九洲药业：诺欣妥相关业务是重要组成部分","url":"https://stock-news.laohu8.com/highlight/detail?id=2641104082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641104082?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:54","pubTimestamp":1780905248,"startTime":"0","endTime":"0","summary":"诺欣妥相关专利延期对公司未来业绩的影响存在不确定性，公司业绩受到宏观经济环境、行业发展趋势、市场竞争、客户需求以及公司经营管理等多重因素影响，具体经营情况详见公司于上海证券交易所网站披露的定期报告及相关公告，敬请广大投资者理性投资，注意投资风险，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800017674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978919","title":"九洲药业：公司积极推出2026年股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640978919?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391947,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是觉得当前股价不够低吗，要把回购审议会议定到6月10日召开？中兴通讯发布回购方案，股价能涨停。公司发布回购方案股价一再新低，公司到底差在哪了？九洲药业回复：您好，感谢您对公司的关注与支持，股价波动受多重非可控因素影响，公司为进一步稳定股价，增强投资者信心，公司积极推出2026年股份回购计划，具体内容请持续关注公司于上海证券交易所网站披露的相关公告，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919994","title":"九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919994","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919994?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391947,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问贵司是否属于能承接后端订单、复杂新分子和全球临床需求的公司呢？九洲药业回复：您好，感谢您对公司的关注与支持，公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239","06978","BK1161","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640677916","title":"九洲药业(603456.SH)：克立硼罗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2640677916","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640677916?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:49","pubTimestamp":1780390154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于克立硼罗的《化学原料药上市申请批准通知书》。该药品是一种磷酸二酯酶4(PDE-4)抑制剂，其制剂克立硼罗软膏适用于3月龄及以上轻度至中度特应性皮炎患者的局部外用治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604503","title":"每周股票复盘：九洲药业（603456）拟回购2-4亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604503?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:05","pubTimestamp":1780167913,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，九洲药业报收于12.64元，较上周的12.83元下跌1.48%。本周，九洲药业5月26日盘中最高价报13.05元。本周关注点公司公告汇总：九洲药业拟以自有资金2亿元至4亿元回购股份，价格不超20元/股。公司公告汇总：回购股份事项需提交2026年6月10日临时股东会审议。回购股份将部分用于股权激励或员工持股计划，部分用于注销并减少注册资本。股权登记日为2026年6月2日，A股股东有权参会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638711505","title":"九洲药业（603456）披露拟回购股份公告，5月27日股价下跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638711505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638711505?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:37","pubTimestamp":1779874622,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，九洲药业报收于12.72元，较前一交易日下跌0.86%，最新总市值为113.14亿元。该股当日开盘12.77元，最高12.96元，最低12.66元，成交额达1.54亿元，换手率为1.35%。近日，浙江九洲药业股份有限公司披露《2026年第一次临时股东会会议资料》。回购股份将部分用于实施股权激励计划或员工持股计划，部分用于注销并减少注册资本。回购实施期限为股东会审议通过之日起12个月内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700034759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351835","title":"九洲药业(603456.SH)拟2亿元至4亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351835","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638351835?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:01","pubTimestamp":1779696067,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，公司拟以自有资金通过集中竞价交易方式回购公司股份，回购股份金额不低于2亿元(含)，不高于4亿元(含)，回购的价格不超过20元/股(含)。本次回购的股份将部分用于后续实施股权激励计划或员工持股计划，部分用于注销并减少注册资本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)拟2亿元至4亿元回购公司股份","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637373441","title":"每周股票复盘：九洲药业（603456）拟注销773.6万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2637373441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637373441?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:51","pubTimestamp":1779562270,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，九洲药业报收于12.83元，较上周的12.99元下跌1.23%。本周，九洲药业5月19日盘中最高价报13.34元。本周关注点公司公告汇总：九洲药业拟注销773.6万股回购股份，注册资本将减少至881,710,028元。九洲药业于2026年5月18日在浙江省台州市椒江区外沙路99号召开2025年年度股东会，出席会议的股东及代理人共766人，代表有表决权股份总数401,288,737股，占公司有表决权股份总数的45.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636013116","title":"股市必读：九洲药业（603456）今年截至5月15日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636013116","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636013116?lang=zh_cn&edition=full","pubTime":"2026-05-18 01:53","pubTimestamp":1779040391,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，九洲药业报收于12.99元，下跌1.14%，换手率1.62%，成交量14.37万手，成交额1.88亿元。交易信息汇总股价提醒5月15日九洲药业收盘报12.99元，跌1.14%，当日成交1436.57万元。该股已连续4日下跌，当年累计跌幅25.05%。资金流向5月15日主力资金净流出2605.79万元，占总成交额13.86%；游资资金净流入426.45万元，占总成交额2.27%；散户资金净流入2179.34万元，占总成交额11.59%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800000800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635940787","title":"5月14日九洲药业创60日新低，富国双债增强债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635940787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635940787?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:27","pubTimestamp":1778747236,"startTime":"0","endTime":"0","summary":"证券之星消息，5月14日九洲药业创60日新低，收盘报13.14元，当日跌2.88%，换手率2.0%，成交量17.76万手，成交额2.36亿元。重仓九洲药业的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为22.32。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为富国基金的富国双债增强债券A。该公募基金现任基金经理为俞晓斌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400028513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634414799","title":"每周股票复盘：九洲药业（603456）拟每10股派1元并注销773.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634414799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634414799?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:55","pubTimestamp":1778352910,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，九洲药业报收于13.69元，较上周的13.79元下跌0.73%。本周，九洲药业5月6日盘中最高价报13.84元。公司公告汇总浙江九洲药业股份有限公司于2025年12月9日召开董事会，审议通过使用不超过10亿元的闲置募集资金进行现金管理的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633835324","title":"长城国瑞证券：给予九洲药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633835324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633835324?lang=zh_cn&edition=full","pubTime":"2026-05-08 11:56","pubTimestamp":1778212605,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦,魏钰琪近期对九洲药业进行研究并发布了研究报告《2025全年业绩稳健增长，新分子平台赋能中长期发展》，给予九洲药业增持评级。2025年，公司特色原料药及中间体业务盈利能力逐步修复，实现收入11.59亿元，同比基本持平；毛利率24.90%，同比提升4.79pct。综合考量，我们将公司评级下调至“增持”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800018730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633839431","title":"九洲药业（603456）披露2025年年度股东会会议资料，5月6日股价下跌1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633839431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633839431?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:31","pubTimestamp":1778059864,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，九洲药业报收于13.6元，较前一交易日下跌1.38%，最新总市值为120.96亿元。近日，浙江九洲药业股份有限公司披露《2025年年度股东会会议资料》。公告显示，公司定于2026年5月18日召开2025年年度股东会，会议将审议包括2025年度董事会工作报告、利润分配预案、年度报告、续聘会计师事务所、董事薪酬确认与计划、投资预算、银行授信、资产抵押、回购股份用途变更及公司章程修订等13项议案。独立董事提交了2025年度履职报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630365276","title":"4月27日九洲药业跌5.84%，富国双债增强债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630365276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630365276?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:26","pubTimestamp":1777278365,"startTime":"0","endTime":"0","summary":"证券之星消息，4月27日九洲药业跌5.84%创60日新低，收盘报14.02元，换手率4.69%，成交量41.75万手，成交额5.94亿元。重仓九洲药业的前十大公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为富国基金的富国双债增强债券A。该公募基金现任基金经理为俞晓斌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700028985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629895489","title":"异动快报：九洲药业（603456）4月24日10点45分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2629895489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629895489?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:50","pubTimestamp":1776999030,"startTime":"0","endTime":"0","summary":"证券之星4月24日盘中消息，10点45分九洲药业（603456）触及跌停板。其所属行业医疗服务目前上涨。领涨股为普瑞眼科。该股为创新药，医药，化学原料药概念热股。4月23日的资金流向数据方面，主力资金净流出1682.84万元，占总成交额8.07%，游资资金净流出1130.54万元，占总成交额5.42%，散户资金净流入2813.38万元，占总成交额13.49%。近5日资金流向一览见下表：九洲药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400032142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629306028","title":"九洲药业(603456.SH)发布一季度业绩，归母净利润1.72亿元，同比下降31.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629306028","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629306028?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:55","pubTimestamp":1776952534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)披露2026年第一季度报告，报告期公司实现营收12.01亿元，同比下降19.43%;归母净利润1.72亿元，同比下降31.22%;扣非净利润1.69亿元，同比下降32.67%。基本每股收益0.19元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"九洲药业(603456.SH)发布一季度业绩，归母净利润1.72亿元，同比下降31.22%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781936517088,"stockEarnings":[{"period":"1week","weight":0.0772},{"period":"1month","weight":0.0011},{"period":"3month","weight":-0.1846},{"period":"6month","weight":-0.2769},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.2612}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江九洲药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"59705人(较上一季度增加4.62%)","perCapita":"14897股","listingDate":"2014-10-10","address":"浙江省台州市椒江区外沙路99号","registeredCapital":"88944万元","survey":" 浙江九洲药业股份有限公司的主营业务是提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是合同定制类、抗感染类、中枢神经类药物、非甾体类药物、降血糖类药、贸易类及其他。公司荣获2025中国医药CDMO企业20强、国家知识产权示范企业、2024年度中国医药工业主营业务收入前100位企业、2025年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉，同时公司已入选富时罗素社会责任指数系列。","listedPrice":15.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九洲药业,603456,九洲药业股票,九洲药业股票老虎,九洲药业股票老虎国际,九洲药业行情,九洲药业股票行情,九洲药业股价,九洲药业股市,九洲药业股票价格,九洲药业股票交易,九洲药业股票购买,九洲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}